

Table S1 Clinicopathologic features of 109 HCC patients

Patient number	Age (years)	Gender	Tumor size (cm)	AFP (ng/mL)	Distant metastasis	Vascular invasion	Involucrum	HBsAg	Cirrhosis	TNM stage	Recurrence
Case 1	45	Male	7	1000	No	Yes	Absent	Negative	Yes	II	No
Case 2	43	Male	3.5	26.1	No	Yes	Incomplete	Positive	Yes	II	No
Case 3	58	Male	4	3.8	No	Yes	Incomplete	Positive	Yes	IIIa	No
Case 4	65	Male	2.5	6.5	No	Yes	Incomplete	Positive	Yes	II	Yes
Case 5	56	Male	11	38	No	Yes	Absent	Positive	Yes	II	Yes
Case 6	43	Male	12	1000	Yes	Yes	Absent	Positive	No	II	Yes
Case 7	52	Male	4	5.4	No	Yes	Incomplete	Positive	Yes	II	No
Case 8	69	Male	14	1000	Yes	Yes	Complete	Positive	Yes	II	Yes
Case 9	55	Male	3	8	No	Yes	Absent	Positive	Yes	II	No
Case 10	62	Female	6	2.1	No	No	Incomplete	Negative	No	II	Yes
Case 11	61	Male	8	1000	Yes	Yes	Absent	Positive	Yes	II	Yes
Case 12	72	Male	3.5	29	No	Yes	Incomplete	Positive	Yes	II	Yes
Case 13	55	Male	2.5	1001	No	No	Complete	Positive	Yes	II	No
Case 14	48	Male	11	1001	Yes	Yes	Absent	Positive	Yes	II	Yes
Case 15	46	Male	6	115	No	No	Complete	Positive	No	IIIa	No
Case 16	49	Male	1.5	170	No	No	Complete	Positive	Yes	II	No
Case 17	56	Male	3	4	No	No	Absent	Negative	No	II	No
Case 18	41	Male	12	1000	No	Yes	Incomplete	Positive	No	II	No
Case 19	48	Male	4	77	No	Yes	Incomplete	Negative	No	II	Yes
Case 20	44	Male	12	273	Yes	Yes	Complete	Positive	Yes	II	Yes
Case 21	22	Male	3	842	No	Yes	Complete	Positive	No	II	No
Case 22	31	Male	15	209	No	Yes	Absent	Positive	Yes	II	Yes
Case 23	74	Male	12	5.2	No	No	Incomplete	Positive	No	II	No
Case 24	69	Female	6	24	No	Yes	Complete	Positive	Yes	II	Yes
Case 25	51	Male	7	86	No	Yes	Absent	Positive	No	IIIa	No
Case 26	41	Male	4.5	1001	No	No	Complete	Positive	Yes	I	No
Case 27	28	Male	16	1001	No	Yes	Absent	Positive	Yes	II	Yes
Case 28	53	Male	3.5	31	No	No	Incomplete	Positive	No	I	Yes
Case 29	45	Male	13	1000	No	Yes	Incomplete	Negative	No	II	No
Case 30	72	Male	5	14	No	Yes	Absent	Positive	Yes	II	Yes
Case 31	36	Male	11	81	No	No	Complete	Positive	Yes	IIIa	No
Case 32	50	Male	4.5	9.6	No	No	Incomplete	Positive	Yes	II	No
Case 33	78	Male	5.5	57	No	No	Incomplete	Negative	Yes	I	No
Case 34	45	Male	13	1000	No	Yes	Absent	Negative	No	II	Yes

Table S1 (continued)

Table S1 (continued)

Patient number	Age (years)	Gender	Tumor size (cm)	AFP (ng/mL)	Distant metastasis	Vascular invasion	Involucrum	HBsAg	Cirrhosis	TNM stage	Recurrence
Case 35	62	Male	11	266	Yes	No	Absent	Negative	No	II	Yes
Case 36	60	Male	6.5	26	No	Yes	Incomplete	Positive	Yes	IIIa	Yes
Case 37	64	Male	3.5	4	No	Yes	Complete	Positive	No	II	Yes
Case 38	52	Male	1.5	123	No	No	Complete	Positive	Yes	I	No
Case 39	48	Female	1.5	1001	No	Yes	Absent	Positive	No	II	No
Case 40	50	Male	4	1000	No	No	Absent	Positive	No	II	Yes
Case 41	58	Male	5.5	19	No	No	Complete	Negative	Yes	I	Yes
Case 42	32	Male	5.5	54	No	No	Complete	Negative	Yes	IIIa	No
Case 43	37	Male	10	1001	No	Yes	Absent	Positive	No	II	No
Case 44	54	Female	1.8	12	No	No	Complete	Positive	Yes	I	No
Case 45	51	Male	6	1001	No	Yes	Absent	Positive	No	II	Yes
Case 46	34	Male	1.4	1086	No	No	Complete	Positive	Yes	I	No
Case 47	40	Male	9	112	No	Yes	Absent	Positive	No	II	Yes
Case 48	54	Male	10	569	No	Yes	Incomplete	Positive	No	II	Yes
Case 49	37	Male	20	1000	No	Yes	Absent	Negative	No	IIIa	No
Case 50	46	Male	5.5	1000	No	Yes	Complete	Negative	No	II	Yes
Case 51	34	Male	2.5	1000	No	No	Complete	Positive	Yes	II	No
Case 52	50	Male	6	56	No	Yes	Incomplete	Positive	No	II	Yes
Case 53	38	Male	13	1000	No	Yes	Absent	Positive	No	II	No
Case 54	58	Male	5	1001	Yes	Yes	Incomplete	Negative	No	II	Yes
Case 55	70	Male	4.5	191	No	No	Complete	Positive	No	II	No
Case 56	54	Male	4	1001	No	No	Incomplete	Negative	No	I	No
Case 57	66	Male	8	30	Yes	Yes	Absent	Positive	Yes	IIIa	Yes
Case 58	28	Male	6.5	732	No	Yes	Absent	Positive	No	IIIb	No
Case 59	51	Male	2.5	507	No	No	Complete	Positive	No	I	No
Case 60	31	Male	3	1000	No	No	Absent	Positive	No	I	No
Case 61	55	Male	1.5	226	No	Yes	Absent	Positive	Yes	I	Yes
Case 62	45	Male	2.8	36	No	No	Absent	Positive	Yes	IIIa	Yes
Case 63	56	Female	6	1000	No	Yes	Complete	Positive	No	II	No
Case 64	49	Female	2	208	No	No	Complete	Positive	No	II	No
Case 65	65	Male	12	267	No	No	Incomplete	Positive	Yes	IV	No
Case 66	76	Female	4	46	No	No	Complete	Positive	Yes	II	No
Case 67	47	Male	4	21	No	Yes	Complete	Positive	Yes	II	No
Case 68	40	Male	8	545	No	Yes	Absent	Negative	No	II	Yes

Table S1 (continued)

Table S1 (continued)

Patient number	Age (years)	Gender	Tumor size (cm)	AFP (ng/mL)	Distant metastasis	Vascular invasion	Involucrum	HBsAg	Cirrhosis	TNM stage	Recurrence
Case 69	42	Male	3	8	No	No	Incomplete	Positive	Yes	I	No
Case 70	48	Male	9	347	No	Yes	Complete	Negative	No	II	No
Case 71	56	Female	2.5	9.2	No	No	Incomplete	Positive	Yes	I	No
Case 72	42	Male	2	19.8	No	No	Complete	Positive	Yes	I	Yes
Case 73	39	Male	5	12	No	Yes	Complete	Positive	Yes	II	Yes
Case 74	68	Male	5	1000	No	Yes	Absent	Positive	No	II	No
Case 75	45	Male	4.3	1001	No	Yes	Complete	Positive	Yes	II	No
Case 76	56	Male	1.2	1001	No	No	Absent	Negative	No	I	No
Case 77	57	Male	2.5	70	No	No	Complete	Negative	No	I	No
Case 78	39	Male	10	1001	Yes	Yes	Complete	Positive	No	III	Yes
Case 79	62	Male	5	11	No	No	Complete	Positive	No	I	Yes
Case 80	41	Male	14	16	Yes	No	Incomplete	Positive	No	I	Yes
Case 81	67	Male	9.5	12	No	No	Complete	Positive	No	IIIa	No
Case 82	40	Male	9	62	No	No	Complete	Positive	No	I	No
Case 83	50	Male	6	2.5	No	No	Complete	Positive	Yes	IIIa	No
Case 84	34	Male	1.6	1001	No	No	Complete	Positive	Yes	I	No
Case 85	66	Male	6	24	Yes	Yes	Complete	Positive	Yes	II	Yes
Case 86	47	Male	8	1001	No	Yes	Absent	Positive	Yes	II	Yes
Case 87	53	Male	2.8	18	No	No	Complete	Positive	No	I	No
Case 88	51	Male	8	12	No	No	Incomplete	Negative	No	I	No
Case 89	53	Male	2	1001	No	No	Complete	Negative	No	I	No
Case 90	54	Female	11	15	No	Yes	Incomplete	Negative	No	IIIa	No
Case 91	49	Male	5.5	179	No	No	Absent	Positive	No	IIIa	No
Case 92	40	Male	3	1001	No	No	Complete	Positive	Yes	I	No
Case 93	44	Male	11	1000	Yes	Yes	Absent	Positive	Yes	II	Yes
Case 94	64	Male	7	40	No	No	Incomplete	Positive	Yes	IIIa	No
Case 95	42	Male	7	17	No	No	Absent	Negative	Yes	I	Yes
Case 96	43	Male	10	63159	No	No	Absent	Positive	No	I	No
Case 97	63	Female	5	247	No	No	Absent	Positive	No	I	No
Case 98	57	Male	7.5	7.1	No	No	Absent	Positive	No	I	No
Case 99	61	Male	10	21	No	No	Absent	Positive	Yes	I	No
Case 100	71	Male	4.5	1001	No	No	Complete	Positive	No	I	No
Case 101	53	Male	9	10	No	No	Complete	Positive	Yes	IIIa	Yes
Case 102	48	Male	6.5	574	No	No	Complete	Positive	Yes	I	No

Table S1 (continued)

Table S1 (continued)

Patient number	Age (years)	Gender	Tumor size (cm)	AFP (ng/mL)	Distant metastasis	Vascular invasion	Involucrum	HBsAg	Cirrhosis	TNM stage	Recurrence
Case 103	50	Male	6.5	1001	No	No	Absent	Positive	Yes	IIIa	Yes
Case 104	62	Female	7	1001	No	No	Absent	Positive	Yes	I	No
Case 105	74	Male	7	1001	No	No	Absent	Positive	Yes	IIIc	Yes
Case 106	56	Male	22	3	No	Yes	Absent	Positive	No	II	Yes
Case 107	47	Male	2.7	94	No	No	Complete	Positive	No	IIIa	No
Case 108	57	Male	9	1000	No	No	Absent	Positive	Yes	IIIa	No
Case 109	57	Male	2	50	No	Yes	Complete	Positive	No	IIIa	Yes

HCC, hepatocellular carcinoma.

Table S2 Relationship between intratumoral PD-L1 expression and clinicopathologic features

Variable	All cases	PD-L1 density		P value
		Low (n=54)	High (n=55)	
Age (years)				0.537
≤50	53	26	27	
>50	56	28	28	
Gender				0.487
Female	11	6	5	
Male	98	48	50	
HBsAg				0.223
Positive	87	41	46	
Negative	22	13	9	
AFP (ng/mL)				0.173
<20	27	16	11	
≥20	82	38	44	
Cirrhosis				0.538
Yes	55	27	28	
No	54	27	27	
Tumor size (cm)				0.531
<5	43	21	22	
≥5	66	33	33	
TNM stage				0.48
I-II	86	42	44	
III-IV	23	12	11	
Distant metastasis				0.189
Yes	12	4	8	
No	97	50	47	
Vascular invasion				0.54
Yes	52	26	26	
No	57	28	29	
Involucrum				0.24
Complete	43	19	24	
Incomplete or absent	66	35	31	
Recurrence				0.04
Yes	45	20	25	
No	64	34	30	

Patients with HCC were divided into PD-L1 Low expression group (whose final density was lower than the median) and High expression group (whose final density was higher than the median). The patient and disease profiles in each group were compared.

Table S3 Relationship between intratumoral HDAC2 + PD-L1 expression and clinicopathologic features

Variable	All cases	HDAC2 + PD-L1 density		P value
		Low (n=35)	High (n=35)	
Age (years)				0.405
≤50	32	17	15	
>50	38	18	20	
Gender				0.5
Female	5	3	2	
Male	65	32	33	
HBsAg				0.383
Positive	56	29	27	
Negative	14	6	8	
AFP (ng/mL)				0.5
<20	19	10	9	
≥20	51	25	26	
Cirrhosis				0.236
Yes	38	21	17	
No	32	14	18	
Tumor size (cm)				0.229
<5	26	11	15	
≥5	44	24	20	
TNM Stage				0.281
I-II	55	26	29	
III-IV	15	9	6	
Distant metastasis				0.367
Yes	10	4	6	
No	60	31	29	
Microvascular invasion				0.316
Yes	37	17	20	
No	33	18	15	
Involucrum				0.309
Complete	25	11	14	
Incomplete or absent	45	24	21	
Recurrence				0.594
Yes	34	17	17	
No	36	18	18	

Patients with HCC were divided into Low HDAC2 + PD-L1 expression group and High expression group. The patient and disease profiles in each group were compared. HCC, hepatocellular carcinoma.




Figure S1 Overall survival (A) and disease-free survival (B) for the high and low HDAC2 expression groups were analyzed by Kaplan-Meier survival analysis. Overall survival (C) and disease-free survival (D) for the combined high and low HDAC2 and PD-L1 expression groups were analyzed by Kaplan-Meier survival analysis.